¹Ü¼ÒÆÅÐÄË®ÂÛ̳

2024 ACP Internal Medicine Board Review Course Recordings

Board Prep Course Recordings

Ensure you're board-exam ready with ACP's 2024 Internal Medicine Board Review Course Recordings—a multimedia, self-study program that delivers multiple study tools for you to review and reinforce the content likely to be questioned on the exams.

View lectures in any order and as often as you like to solidify your knowledge. These on-demand multimedia sessions include 39+ hours of content and more than 250 board-style questions. ACP’s Board Review Course Recordings Package breaks the lectures into targeted, short single-question segments, so you can create a custom study schedule. 

Copyright 2024 ¹Ü¼ÒÆÅÐÄË®ÂÛ̳. All Rights Reserved.

CME/MOC:

Up to 37.5 AMA PRA Category 1 Credits ™ and MOC Points
Expires September 02, 2027   active

Cost:

Discounted to Members

Format:

Interactive Multi-Media

Product:

Board Prep Course Recordings

ACP's board prep recordings are ideal for those who enjoy watching lectures at their own pace. Videos were recorded live from ACP’s Internal Medicine Board Review Course or MOC Exam Prep Course. Combining live courses and the course recordings are an effective option for a blended learning approach. Stream the sessions to your device or download for offline study.

Faculty Disclosures

The individuals listed below have relevant financial relationships with companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. No other individuals in control of content for this activity have any relevant financial relationships to disclose. All relevant financial relationships have been mitigated. 

Rashmi Chugh, MD

  • Grant/Contract:  Pfizer Inc., Janssen Biotech, Advenchen, Plexxikon Inc., GlaxoSmithKline, AstraZeneca, Epizyme Inc., Mundipharma, Cornerstone Pharmaceuticals, PTC Therapeutics Inc., Astex Pharmaceuticals, Qilu Puget Sound, AADi, Ayala, Kronos Bio, Springworks, Cogent Therapeutics LLC
  • Consultant:  Jazz Pharmaceuticals, Inhibrx Inc. 

Laura Mariani, MD, MS 

  • Grant/Contract:  Boehringer Ingelheim, Reliant Glycosciences 
  • Consultant:  Calliditas Therapeutics, Chinook Therapeutics, Travere Therapeutics Inc. 

Dejan Micic, MD 

  • Consultant:  Takeda Pharmaceutical Company, Ironwood Pharmaceuticals Inc. 

Frank Wang, MD 

  • Grant/Contract:  AbbVie 
  • Consultant:  Galderma Laboratories L.P., ET Browne Company 

Galen T. Foulke, MD  

  • Consultant: AstraZeneca  

Rakhi Teena Kohli, MD, MS, FIDSA  

  • Consultant: Theratechnologies, Inc.  

Farah Morgan, MD  

  • Owner/Partnership: Dashuri 

Shayna Sarosiek, MD  

  • Grant/Contract: ADC Therapeutics 
  • Consultant: BeiGene USA, Cellectar Biosciences  

Accreditation Statement

The ¹Ü¼ÒÆÅÐÄË®ÂÛ̳ (ACP) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. 

The ACP designates this enduring for a maximum of 37.5 AMA PRA Category 1 Credit(s)â„¢. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 37.5 medical knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.